Clinical Overview > Gland/Organ > Heart
You are looking at 11 - 14 of 14 items
Search for other papers by Michal Barabas in
Google Scholar
PubMed
Search for other papers by Isabel Huang-Doran in
Google Scholar
PubMed
Search for other papers by Debbie Pitfield in
Google Scholar
PubMed
Search for other papers by Hazel Philips in
Google Scholar
PubMed
Search for other papers by Manoj Goonewardene in
Google Scholar
PubMed
Search for other papers by Ruth T Casey in
Google Scholar
PubMed
IMED Biotech Unit, Clinical Discovery Unit, AstraZeneca, Cambridge, UK
Search for other papers by Benjamin G Challis in
Google Scholar
PubMed
Summary
A 67-year-old woman presented with a generalised rash associated with weight loss and resting tachycardia. She had a recent diagnosis of diabetes mellitus. Biochemical evaluation revealed elevated levels of circulating glucagon and chromogranin B. Cross-sectional imaging demonstrated a pancreatic lesion and liver metastases, which were octreotide-avid. Biopsy of the liver lesion confirmed a diagnosis of well-differentiated grade 2 pancreatic neuroendocrine tumour, consistent with metastatic glucagonoma. Serial echocardiography commenced 4 years before this diagnosis demonstrated a progressive left ventricular dilatation and dysfunction in the absence of ischaemia, suggestive of glucagonoma-associated dilated cardiomyopathy. Given the severity of the cardiac impairment, surgical management was considered inappropriate and somatostatin analogue therapy was initiated, affecting clinical and biochemical improvement. Serial cross-sectional imaging demonstrated stable disease 2 years after diagnosis. Left ventricular dysfunction persisted, however, despite somatostatin analogue therapy and optimal medical management of cardiac failure. In contrast to previous reports, the case we describe demonstrates that chronic hyperglucagonaemia may lead to irreversible left ventricular compromise. Management of glucagonoma therefore requires careful and serial evaluation of cardiac status.
Learning points:
-
In rare cases, glucagonoma may present with cardiac failure as the dominant feature. Significant cardiac impairment may occur in the absence of other features of glucagonoma syndrome due to subclinical chronic hyperglucagonaemia.
-
A diagnosis of glucagonoma should be considered in patients with non-ischaemic cardiomyopathy, particularly those with other features of glucagonoma syndrome.
-
Cardiac impairment due to glucagonoma may not respond to somatostatin analogue therapy, even in the context of biochemical improvement.
-
All patients with a new diagnosis of glucagonoma should be assessed clinically for evidence of cardiac failure and, if present, a baseline transthoracic echocardiogram should be performed. In the presence of cardiac impairment these patients should be managed by an experienced cardiologist.
Search for other papers by Anastasia Dimakopoulou in
Google Scholar
PubMed
Search for other papers by Karunakaran Vithian in
Google Scholar
PubMed
Search for other papers by David Gannon in
Google Scholar
PubMed
Search for other papers by Allan Harkness in
Google Scholar
PubMed
Summary
A 55-year-old female patient presented to the endocrine clinic with Grave's disease. She was initially treated with carbimazole. After an early relapse, a decision was made to proceed with radioactive iodine therapy. Four days after radioiodine administration, she presented to the emergency department with chest tightness and dyspnea due to heart failure. Biochemistry revealed thyrotoxicosis and significantly elevated Troponin-T. There was ST segment elevation on electrocardiography. However, coronary angiography was normal. Ventricular function was fully restored after 6 weeks of supportive medical management. A diagnosis of stress cardiomyopathy following radioactive iodine therapy was made. This is the second case reported in the literature so far to the best of our knowledge.
Learning points
-
Stress cardiomyopathy in the context of radiation thyroiditis is a rare complication following radioiodine therapy.
-
A degree of awareness is essential because the approach is multidisciplinary. Management is mainly supportive and cardiac dysfunction is completely reversible in most cases.
-
The pathogenesis of this condition remains unclear. Post-menopausal women and susceptible individuals appear to be pre-disposed.
Search for other papers by Kun Zhang in
Google Scholar
PubMed
Search for other papers by Lukas J Lehner in
Google Scholar
PubMed
Search for other papers by Damaris Praeger in
Google Scholar
PubMed
Search for other papers by Gert Baumann in
Google Scholar
PubMed
Search for other papers by Fabian Knebel in
Google Scholar
PubMed
Search for other papers by Marcus Quinkler in
Google Scholar
PubMed
Search for other papers by Torsten K Roepke in
Google Scholar
PubMed
Summary
Neuroendocrine tumours (NETs) represent a broad spectrum of tumours, of which the serotonin-producing carcinoid is the most common and has been shown to cause right ventricular heart failure. However, an association between heart failure and NETs other than carcinoid has not been established so far. In this case report, we describe a 51-year-old patient with a glucagon-producing NET of the pancreas who developed acute heart failure and even cardiogenic shock despite therapy. Heart failure eventually regressed after initialising i.v. treatment with the somatostatin analogue octreotide. Chromogranin A as a tumour marker was shown to be significantly elevated, and it decreased with clinical improvement of the patient. The effects of long-time stimulation of glucagon on the myocardium have not been studied yet; however, sarcoplasmic reticulum calcium leak can be discussed as a possible mechanism for glucagon-induced heart failure.
Learning points
-
Glucagonoma can be a cause for heart failure.
-
i.v. infusion of octreotide can be successfully used to treat glucagonoma-induced acute heart failure.
-
We suggest that cardiac function should be monitored in all NET patients.
Search for other papers by M S Draman in
Google Scholar
PubMed
Search for other papers by H Thabit in
Google Scholar
PubMed
Search for other papers by T J Kiernan in
Google Scholar
PubMed
Search for other papers by J O'Neill in
Google Scholar
PubMed
Search for other papers by S Sreenan in
Google Scholar
PubMed
Search for other papers by J H McDermott in
Google Scholar
PubMed
Summary
Silent myocardial ischaemia (SMI), defined as objective evidence of myocardial ischaemia in the absence of symptoms, has important clinical implications for the patient with coronary artery disease. We present a dramatic case of SMI in a diabetes patient who attended annual review clinic with ST elevation myocardial infarction. His troponin was normal on admission but raised to 10.7 ng/ml (normal <0.5) when repeated the next day. His angiogram showed diffused coronary artery disease. We here discuss the implications of silent ischaemia for the patient and for the physician caring for patients with diabetes.
Learning points
-
Silent myocardial ischaemia (SMI) is an important clinical entity.
-
SMI is common and occurs with increased frequency in patients with diabetes.
-
SMI is an independent predictor of mortality.
-
Recognition may lead to early intervention.